冲动控制障碍和多巴胺受体激动症在帕金森病患者:临床影响
Nils M Tangedal1, Ole-Bjørn Tysnes2
1Faculty of medicine, University of Bergen, Bergen, Norway.
Parkinsonism & related disorders
|December 12, 2025
概括
对于帕金森病 (PD) 的多巴胺激动剂 (DA) 会增加冲动控制障碍 (ICD) 的风险,特别是D3受体激动剂. 延长释放配方和更广泛的受体简介可能会减轻这种风险,但建议谨慎使用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 冲动控制障碍 (ICD),如强迫性购物和博,在接受多巴胺激动剂 (DA) 治疗的帕金森病 (PD) 患者中是显著的负担.
- 虽然DA提供了运动效益和较低的运动障碍风险比利沃多巴,他们的协会与ICDs需要仔细的临床考虑.
研究的目的:
- 审查DA的多巴胺受体亚型选择性和PD患者发展ICD的风险之间的关系.
- 探索这些发现对临床实践和DA选择的影响.
主要方法:
- 文献综述检查了多巴胺受体激动性和帕金森病中ICD发展的研究.
- 分析包括受体亚型选择性,先发性特征,遗传倾向和药物配方 (ER/IR) 在内的因素.
主要成果:
- 与具有更广泛的受体配置文件的DA相比,D3受体激动症始终与更高的ICD风险有关.
- 延长释放 (ER) 配方也可能影响ICD风险,可能与即时释放 (IR) 配方不同.
结论:
- 具有更广泛多巴胺受体配置和ER配方的DA可能会降低PD治疗中的ICD风险.
- 尽管有潜在的缓解策略,但DA具有显著的ICD风险,这证明了它们的使用限制在临床上必要的情况.
相关概念视频
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232


